Nomafen (Tamoxifen Citrate)

Tamoxifen citrate, the active ingredient in Nomafen, is a selective estrogen receptor modulator presented as an oral tablet for oral use. It antagonizes estrogen receptors in breast tissue and is employed in the treatment and prevention of estrogen‑dependent breast cancer in women and men.

GNH USA supplies Nomafen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides reliable global distribution.

Tamoxifen citrate is used in hormone‑responsive breast cancer and related conditions, acting on estrogen‑dependent pathways.

- Early‑stage estrogen‑receptor‑positive breast cancer: Reduces recurrence risk after surgery and radiation. - Metastatic breast cancer: Improves overall survival and delays disease progression. - Ductal carcinoma in situ (DCIS): Decreases the likelihood of invasive cancer development. - High‑risk women for breast cancer prevention: Lowers incidence of first‑time breast cancer.

Tamoxifen citrate may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Hot flashes: Transient episodes of warmth and sweating. - Nausea: Mild to moderate gastrointestinal discomfort. - Menstrual irregularities: Changes in cycle length or flow. - Fatigue: Persistent low‑energy feeling. - Vaginal dryness or discharge: Local estrogen‑related changes. - Weight gain: Modest increase in body weight.

Serious or Rare Side Effects: - Thromboembolic events: Deep vein thrombosis or pulmonary embolism. - Endometrial cancer: Uncommon but serious uterine malignancy. - Severe liver toxicity: Elevated transaminases or hepatitis. - Anaphylactic reaction: Immediate hypersensitivity requiring emergency care. - Visual disturbances: Rare optic neuritis or retinopathy.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for adverse events.

- Liver function monitoring: Perform baseline and periodic liver enzyme tests. - Thromboembolic risk assessment: Evaluate history of clotting disorders before use. - Endometrial surveillance: Conduct regular gynecologic examinations for abnormal bleeding. - Contraception counseling: Advise effective birth control for women of childbearing potential. - Pregnancy avoidance: Discontinue if pregnancy is confirmed or suspected. - Store at room temperature: Keep in the original container, protect from moisture and direct sunlight.

Tamoxifen citrate can interact with several medications, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): Reduce conversion to active metabolites. - Estrogen‑containing hormonal therapies: Counteract tamoxifen’s antagonistic effect in breast tissue. - Anticoagulants (e.g., warfarin): Increase risk of bleeding.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): May lower tamoxifen plasma levels. - NSAIDs: Potential additive effect on gastrointestinal irritation. - SSRIs with mild CYP2D6 inhibition (e.g., sertraline): May modestly affect tamoxifen metabolism.